Focused Expertise ChanTest's specialization in ion channel and GPCR safety testing positions it as a strategic partner for pharmaceutical companies seeking accurate and comprehensive nonclinical cardiac safety assessments, creating opportunities for customized testing services and reagents.

Established Reputation Having served over 300 global pharma and biotech clients since 1998, ChanTest demonstrates a proven track record and industry trust, opening avenues for expanding partnerships in early-stage drug discovery and regulatory safety screening.

Market Leadership Recognized as the most trusted provider in ion channel screening since 2006, ChanTest's dominant position offers a platform to introduce new assay solutions, diagnostic tools, or expanded service offerings to existing loyal customers.

Growth Potential With revenue estimated between $1M and $10M and a niche focus, there is an opportunity to leverage strategic marketing and outreach to grow customer awareness, attract larger clients, or develop new service modules for emerging therapeutics.

Innovation & Quality ChanTest's commitment to high-quality, validated cell lines and safety testing creates sales opportunities in supplying specialized reagents and clinical research tools to other CROs and research institutions seeking reliable nonclinical testing sources.